Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, Maryland, USA.
Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, Maryland, USA
BMJ Open. 2020 Dec 21;10(12):e034844. doi: 10.1136/bmjopen-2019-034844.
To assess the association of fluoroquinolone use with tendon ruptures compared with no fluoroquinolone and that of the four most commonly prescribed non-fluoroquinolone antibiotics in the USA.
Retrospective observational study.
US seniors enrolled in the federal old-age, survivor's insurance programme.
1 009 925 Medicare fee-for-service beneficiaries and their inpatient, outpatient, prescription drug records were used.
Seven oral antibiotics, fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) and amoxicillin, amoxicillin-clavulanate, azithromycin and cephalexin.
All tendon ruptures combined, and three types of tendon ruptures by anatomic site, Achilles tendon rupture, rupture of rotator cuff and other tendon ruptures occurred in 2007-2016.
Of three fluoroquinolones, only levofloxacin exhibited a significant increased risk of tendon ruptures-16% (HR=1.16; 95% CI 1.06 to 1.28), and 120% (HR=2.20; 95% CI 1.50 to 3.24) for rotator cuff and Achilles tendon rupture, respectively, in the ≤30 days window. Ciprofloxacin (HR=0.96; 95% CI 0.89 to 1.03) and moxifloxacin (HR=0.59; 95% CI 0.37 to 0.93) exhibited no increased risk of tendon ruptures combined.Among the non-fluoroquinolone antibiotics, cephalexin exhibited risk of combined tendon ruptures (HR=1.31; 95% CI 1.22 to 1.41) and modest to large risks across all anatomic rupture sites (HRs 1.19-1.93) at ≤30 days window. Notably, the risk of levofloxacin never exceeded the risk of the non-fluoroquinolone, cephalexin in any comparison.
In our study, fluoroquinolones as a class were not associated with the increased risk of tendon ruptures. Neither ciprofloxacin nor moxifloxacin exhibited any risk for tendon ruptures. Levofloxacin did exhibit significant increased risk. Cephalexin with no reported effect on metalloprotease activity had an equal or greater risk than levofloxacin; so we question whether metalloprotease activity has any relevance to observed associations with tendon rupture. Confounding by indication bias may be more relevant and should be given more consideration as explanation for significant associations in observational studies of tendon rupture.
评估与未使用氟喹诺酮类药物相比,氟喹诺酮类药物与美国最常开的四种非氟喹诺酮类抗生素与肌腱断裂的关联。
回顾性观察性研究。
美国老年人参加联邦老年和遗属保险计划。
1009925 名医疗保险收费服务受益人和他们的住院、门诊、处方药记录被使用。
七种口服抗生素,氟喹诺酮类(环丙沙星、左氧氟沙星、莫西沙星)和阿莫西林、阿莫西林-克拉维酸、阿奇霉素和头孢氨苄。
2007-2016 年期间所有肌腱断裂(合计)和三种解剖部位的三种肌腱断裂(跟腱断裂、肩袖撕裂和其他肌腱断裂)。
三种氟喹诺酮类药物中,只有左氧氟沙星显示出肌腱断裂的显著风险增加-30 天内分别为 16%(HR=1.16;95%CI 1.06 至 1.28)和 120%(HR=2.20;95%CI 1.50 至 3.24),肩袖和跟腱撕裂。环丙沙星(HR=0.96;95%CI 0.89 至 1.03)和莫西沙星(HR=0.59;95%CI 0.37 至 0.93)没有增加肌腱断裂的风险。在非氟喹诺酮类抗生素中,头孢氨苄在 30 天内显示出联合肌腱断裂的风险(HR=1.31;95%CI 1.22 至 1.41),在所有解剖部位的断裂风险都有适度到较大(HRs 1.19-1.93)。值得注意的是,左氧氟沙星的风险从未超过非氟喹诺酮类药物头孢氨苄的任何比较风险。
在我们的研究中,氟喹诺酮类药物作为一类药物与肌腱断裂的风险增加无关。环丙沙星和莫西沙星均未显示出任何肌腱断裂的风险。左氧氟沙星确实显示出显著增加的风险。头孢氨苄没有报告对金属蛋白酶活性的影响,其风险与左氧氟沙星相同或更大;因此,我们质疑金属蛋白酶活性与观察到的与肌腱断裂的关联是否有任何关系。以适应症为导向的混杂偏倚可能更为相关,应更多地考虑将其作为观察性肌腱断裂研究中显著关联的解释。